All In Biotech

Drug Trial Radar · NCT05162222

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

An Open-label, Randomized, 2-Period Crossover Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose Pharmacokinetics of Danicamtiv in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Dec 15, 2021

Primary completion

Jul 8, 2022

Study completion Jul 8, 2022

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of co-administration of itraconazole or diltiazem on the single-dose pharmacokinetics of danicamtiv in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • DanicamtivDrug

    Specified dose on specified days

  • ItraconazoleDrug

    Specified dose on specified days

  • DiltiazemDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 17 days
  2. Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))Time frame: Up to 17 days
  3. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))Time frame: Up to 17 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit - Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.